NeoPharm Co Ltd
KOSDAQ:092730
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
NeoPharm Co Ltd
KOSDAQ:092730
|
KR |
|
Talon Metals Corp
TSX:TLO
|
VG |
|
Inter & Co Inc
NASDAQ:INTR
|
BR |
|
Green Cures & Botanical Distribution Inc
OTC:GRCU
|
US |
|
R
|
Retech Technology Co Ltd
ASX:RTE
|
CN |
|
V
|
Vicostone JSC
VN:VCS
|
VN |
Wall Street
Price Targets
Price Targets Summary
NeoPharm Co Ltd
According to Wall Street analysts, the average 1-year price target for NeoPharm Co Ltd is 24 480 KRW with a low forecast of 24 240 KRW and a high forecast of 25 200 KRW.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is NeoPharm Co Ltd's stock price target?
Price Target
24 480
KRW
According to Wall Street analysts, the average 1-year price target for NeoPharm Co Ltd is 24 480 KRW with a low forecast of 24 240 KRW and a high forecast of 25 200 KRW.
What is NeoPharm Co Ltd's Revenue forecast?
Projected CAGR
12%
For the last 13 years the compound annual growth rate for NeoPharm Co Ltd's revenue is 16%. The projected CAGR for the next 3 years is 12%.
What is NeoPharm Co Ltd's Operating Income forecast?
Projected CAGR
15%
For the last 13 years the compound annual growth rate for NeoPharm Co Ltd's operating income is 26%. The projected CAGR for the next 3 years is 15%.
What is NeoPharm Co Ltd's Net Income forecast?
Projected CAGR
5%
For the last 13 years the compound annual growth rate for NeoPharm Co Ltd's net income is 28%. The projected CAGR for the next 3 years is 5%.
